18 December 2023 - Keytruda now approved for 26 indications in the EU, including seven in gastro-intestinal cancers. ...
18 December 2023 - The EMA and the Heads of Medicines Agencies have published an artificial intelligence workplan to 2028, ...
15 December 2023 - EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping ...
15 December 2023 - Biogen announced the CHMP of the EMA recommended marketing authorisation for Skyclarys (omaveloxolone) for the treatment ...
17 December 2023 - Astellas contributed to the development of a paediatric formulation to treat schistosomiasis as a member of ...
15 December 2023 - Positive opinion based on Phase 3 ADVANCE-CIDP 1 study, which met its primary endpoint demonstrating a statistically ...
15 December 2023 - If approved by the European Commission, patients 12 years of age and older with severe sickle cell ...
14 December 2023 - These regulatory milestones bring CSL one step closer to delivering on our promise to patients with ...
14 December 2023 - Apellis Pharmaceuticals announced today an update on the on-going review of its marketing authorisation application for ...
12 December 2023 - The European Commission, the Heads of Medicines Agencies and EMA have published the first version of the ...
11 December 2023 - Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend ...
11 December 2023 - Vueway is a new, highly stable, macrocyclic gadolinium-based contrast agent (GBCA) for contrast-enhanced magnetic resonance imaging (CE-MRI): ...
11 December 2023 - European Commission also converts previous conditional approval for Jemperli to full approval as a monotherapy for ...
11 December 2023 - The EMA has published a draft agenda for this week's CHMP meeting. ...
10 December 2023 - First in class treatment option reduces number and intensity of hot flashes and night sweats ...